Researchers have shown that Type-2 diabetes is caused by fat accumulating in the pancreas and that losing less than one gram of that fat through weight loss reverses the condition.
December 2015
Almonds contain 20 percent lower calories than originally believed, claims a study released.
In addition to treating depression, a commonly used antidepressant medication also protects against compounds that can cause memory loss and dementia, new research has found.
Recently approved antiviral medications for hepatitis C could reduce the prevalence of the blood-borne infection by more than 80 percent, researchers have estimated.
Health Minister J.P. Nadda on Tuesday announced that the National AIDS Control Programme will continue as a central sector scheme, following concerns over the ability of some states on contributing their share to the programme.
Psoriasis, a chronic inflammatory skin disease, can be easily deal with by homegrown solutions.
Pre-existing asthma may be a strong predictor of future chronic migraine attacks in individuals experiencing occasional migraine headaches, according to researchers from the University of Cincinnati (UC) in the US.
Upsher-Smith Laboratories, Inc. (Upsher-Smith), through its wholly-owned UK subsidiary Proximagen Ltd. joined with Roche for the further development of a novel, oral small molecule inhibitor of Vascular Adhesion Protein 1 (VAP-1), a cell-adhesion molecule that may be effective in the treatment of inflammatory diseases. The VAP-1 inhibitor is currently in phase II clinical development.
To mark World AIDS Day, the Bristol-Myers Squibb Foundation today announced 16 grants totaling $3.5 million for programs in Africa that strengthen HIV services for adolescents and the elderly, raise awareness and access to health care for women co-diagnosed with HIV and breast or cervical cancer, and build community capacity and integrate treatment for HIV/tuberculosis (TB) co-infection.
Janssen Biotech, Inc. and Janssen-Cilag International NV (Janssen) announced today the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) and a Grouped Type II Variation/Extension Application to the European Medicines Agency (EMA) seeking approval of STELARA® (ustekinumab) for the treatment of adult patients with moderately to severely active Crohn’s disease. Crohn’s disease is a chronic inflammatory condition of the gastrointestinal tract that affects approximately 700,000 Americans1 and nearly 250,000 Europeans.2
RECOMMENDED POSTS
Subscribe with us
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
